相关实验视频

Updated: Jan 7, 2026

In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells

In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells

Published on: May 15, 2014

针对分泌的PLA₂与EGFR和维丁的相互作用,以阻止前列腺瘤的生长

Timothy J Mann^1,2, Ryung Rae Kim³, Mila Sajinovic^1,2

¹School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.

Cell death & disease

|December 20, 2025

概括

分泌的脂酶A2人类IIA组 (hGIIA) 通过蛋白质相互作用驱动前列腺癌 (PCa) 的进展. 新型循环cF和c2抑制了这些相互作用,显示了高级PCa的治疗潜力.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物化学生物化学

背景情况:

分泌的脂酶A2人群IIA (hGIIA) 在前列腺癌 (PCa) 中过度表达,与恶性瘤相关.
虽然hGIIA具有天生的免疫作用,但其蛋白质-蛋白质相互作用是PCa病理学的关键驱动因素.

研究的目的:

通过蛋白质-蛋白质相互作用研究hGIIA在PCa进展中的作用.
为PCa治疗开发和评估针对这些相互作用的新型抑制剂.

主要方法:

从hGIIA结构中衍生出的循环 (cF,c2) 的开发.
对hGIIA与表皮生长因子受体 (EGFR) 和PCa细胞中的维丁相互作用的分析.
在体内研究中,使用了对雄激素敏感,抗和抗雄激素独立的PCa模型.

主要成果:

hGIIA与EGFR相互作用,增加了前列腺素E2的产生;c2抑制了这一点.
hGIIA与维门丁结合,调节其流通;c2阻断这种相互作用,诱导亡.
cF和c2在低剂量 (0.1毫克/千克) 的体内显著抑制瘤,没有观察到毒性,口服生物可用性和细胞透性.

结论:

hGIIA作为一种天生的免疫效应剂,通过特定的蛋白质相互作用调节PCa炎症和进展.
新的hGIIA蛋白质-蛋白质相互作用抑制剂 (cF,c2) 显示出对转移性抗PCa的治疗前景.
针对hGIIA,EGFR和维门相互作用,为晚期前列腺癌提供了一个新的治疗策略.

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...